Move to topTop
TOKYO, JAPAN—Terumo Corporation (TSE: 4543) announced that it has been selected as an "A-List" company in the "Water Security" category of CDP 2024 by the international non-profit organization CDP*.
 

Guided by its Group Mission of "Contributing to Society through Healthcare," Terumo aims to realize a sustainable society balanced with a steady growth of the company by listening broadly to the voices of patients, healthcare professionals, and stakeholders. As part of the Terumo Group Sustainability Policy, Terumo positions the reduction of environmental burden as one of the most important sustainability priorities. Recognizing water as a vital resource in its business activities, Terumo sets medium- to long-term goals for its effective use of water resources, while striving to prevent pollution and manage risks.

Terumo will continue to contribute to the realization of a sustainable and healthy society by not only providing valuable solutions but also actively working to solve social and environmental issues surrounding healthcare.

 

* CDP is a global non-profit organization that runs the world’s only independent environmental disclosure system. Partnering with leaders in enterprise, capital, policy and science, CDP surfaces the information needed to enable Earth-positive decisions. More than 24,800 companies and 1,100 cities, states and regions disclosed their environmental impacts through CDP in 2024. 
https://www.cdp.net/en/about

 

Terumo's efforts towards effective use of water resources

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.